{"id":54621,"date":"2026-09-15T19:20:32","date_gmt":"2026-09-15T19:20:32","guid":{"rendered":"https:\/\/cp.snarskis.lt\/index.php\/2026\/09\/15\/magnitude-biosciences-pritrauke-15-mln-euru-in-vivo-atrankos-platforma-zada-paspartinti-vaistu-paieska\/"},"modified":"2026-09-15T19:20:32","modified_gmt":"2026-09-15T19:20:32","slug":"magnitude-biosciences-pritrauke-15-mln-euru-in-vivo-atrankos-platforma-zada-paspartinti-vaistu-paieska","status":"publish","type":"post","link":"https:\/\/cp.snarskis.lt\/index.php\/2026\/09\/15\/magnitude-biosciences-pritrauke-15-mln-euru-in-vivo-atrankos-platforma-zada-paspartinti-vaistu-paieska\/","title":{"rendered":"\u201eMagnitude Biosciences\u201c pritrauk\u0117 1,5 mln. eur\u0173: in vivo atrankos platforma \u017eada paspartinti vaist\u0173 paie\u0161k\u0105"},"content":{"rendered":"<h2>Investicija ir planai<\/h2>\n<p>Durhamo universiteto startuolis \u201eMagnitude Biosciences\u201c, veikiantis kaip kontraktini\u0173 tyrim\u0173 organizacija, pritrauk\u0117 1,5 mln. eur\u0173 investicij\u0105. L\u0117\u0161os bus skirtos komercializuoti ir i\u0161pl\u0117sti \u201eVivoScan\u201c \u2013 in vivo didel\u0117s spartos atrankos platform\u0105, skirt\u0105 ankstyvajai vaist\u0173 paie\u0161kai.<\/p>\n<p>Investicij\u0173 raundui vadovavo \u201eNorthstar Ventures\u201c per regioninius fondus, prisid\u0117jo \u201eMaven\u201c valdomi fondai ir nauji verslo angelai. Kartu su priva\u010diomis investicijomis bendrov\u0117 taip pat u\u017esitikrino papildom\u0105 253 000 eur\u0173 \u201eInnovate UK\u201c investuotoj\u0173 partneryst\u0117s grant\u0105.<\/p>\n<p>\u201eM\u016bs\u0173 ambicija \u2013 tapti pirm\u0105ja \u012fmone, galin\u010dia atrinkti milijonus jungini\u0173 visame organizme. \u0160i investicija \u012f \u201eVivoScan\u201c suteikia prog\u0105 tai paversti realybe ir i\u0161 esm\u0117s pakeisti vaist\u0173 paie\u0161kos mast\u0105 bei greit\u012f\u201c, \u2013 sak\u0117 \u201eMagnitude Biosciences\u201c vadov\u0117 dr. Fozia Saleem.<\/p>\n<h2>Kas yra \u201eVivoScan\u201c?<\/h2>\n<p>\u201eVivoScan\u201c remiasi ma\u017eais laboratoriniais nematodais C. elegans, kurie pla\u010diai naudojami biologiniuose tyrimuose kaip viso organizmo modelis. Platforma jungia automatizuot\u0105 vaizdinim\u0105, robotik\u0105 ir DI analiz\u0119, kad b\u016bt\u0173 galima greitai \u012fvertinti, kaip organizmas reaguoja \u012f skirtingus cheminius junginius.<\/p>\n<p>Tokio tipo in vivo atranka gali papildyti \u012fprastas l\u0105steli\u0173 ar biochemines sistemas, nes leid\u017eia anks\u010diau pamatyti platesnius organizmo poky\u010dius. Bendrov\u0117 akcentuoja, kad tai svarbu srityse, kuriose sunku prognozuoti poveik\u012f vien pagal l\u0105steli\u0173 testus, pavyzd\u017eiui, sen\u0117jimo biologijoje ar neurodegeneracini\u0173 lig\u0173 tyrimuose.<\/p>\n<p>\u201eKuriame platform\u0105, kuri ne tik leid\u017eia patikrinti daugiau jungini\u0173. \u201eVivoScan\u201c generuoja turtingus viso organizmo biologinius duomenis, padedan\u010dius geriau suprasti poveik\u012f sveikatai, sen\u0117jimui ir ligoms\u201c, \u2013 sak\u0117 dr. Fozia Saleem.<\/p>\n<h2>Platesnis kontekstas Europoje<\/h2>\n<p>\u201eMagnitude Biosciences\u201c \u017eingsnis sutampa su platesne Europos tendencija investuoti \u012f platformas, kurios spartina ikiklinikinius tyrimus ir didina j\u0173 informatyvum\u0105. Pastaraisiais metais vis daugiau d\u0117mesio skiriama sprendimams, galintiems suma\u017einti brangiai kainuojan\u010di\u0173 nes\u0117kmi\u0173 rizik\u0105 v\u0117lesn\u0117se klinikini\u0173 tyrim\u0173 stadijose.<\/p>\n<p>\u0160alia klasikin\u0117s didel\u0117s spartos atrankos laboratorijose ry\u0161k\u0117ja dvi kryptys: pa\u017eangesni biologiniai modeliai ir duomen\u0173 analiz\u0117s automatizavimas. In vivo modeliai bei kompiuterin\u0117 analiz\u0117 leid\u017eia tyr\u0117jams grei\u010diau i\u0161ry\u0161kinti ne tik kandidato efektyvum\u0105, bet ir galimus saugumo signalus ar netik\u0117t\u0105 sistemin\u012f poveik\u012f.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201eMagnitude Biosciences\u201c pritrauk\u0117 1,5 mln. eur\u0173 \u201eVivoScan\u201c pl\u0117trai \u2013 in vivo atrankos platforma su DI siekia pagreitinti vaist\u0173 paie\u0161k\u0105.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[4093,42143,42142,42139,1040,42141,42140],"miestas":[],"class_list":["post-54621","post","type-post","status-publish","format-standard","hentry","category-finansai","tag-biotechnologijos","tag-c-elegans","tag-ikiklinikiniai-tyrimai","tag-magnitude-biosciences","tag-startuoliai","tag-vaistu-paieska","tag-vivoscan"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/54621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=54621"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/54621\/revisions"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=54621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=54621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=54621"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=54621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}